BioSpace News Archive

Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.

Smith+Nephew, the global medical technology business, is proud to announce the creation of a purpose built digital surgery and robotics innovation centre, based in Munich, Germany.

Orexo AB, announces that the company has successfully completed the pivotal trial for its lead pharmaceutical pipeline asset, OX124.

NorthSea Therapeutics B.V., a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, announces the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience™ 2021 of the American Association for the Study of Liver Diseases, which was held online from November 12-15.

AOBiome’s 547 subject Phase 2b trial for Treatment of Pruritus (Itch) Associated with Atopic Dermatitis (Eczema) successfully completes its recruitment goal

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled “Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro” from the University of California, San Francisco.

Spineart USA Inc. announced today that the 100th surgery has been performed in their combined single-level and two-level U.S. Investigational Device Exemption (IDE) Clinical Trials of the BAGUERA® C Cervical Disc Prosthesis.

Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement-targeted therapies to treat immune-mediated diseases, announced the appointment of Teri Loxam as Chief Operating Officer and Chief Financial Officer.

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.